返回 Agenda
Session 7: Interchangeability
Session Chair(s)
Cecil J. Nick, MS
FTOPRA, Vice President (Technical)
Parexel Consulting, United Kingdom
Biosimilar access and adoption is dependent on Biosimilars being available in the market place. A wide variety of commercial models exist varying from national tendering through to individual commercial plan acceptance. These models will be variously impacted by or will impact the concepts of interchangeability, switching and substitution. The session will also address the practical differences between each of these terms. It will specifically address regulatory considerations/ expectations related to interchangeability and the impact of such designation on the future market place dynamics and adoption. Scientific concepts and their application to achieve interchangeability designation will be discussed.
Speaker(s)
The Science of Interchangeability
Hillel P Cohen, PhD
Sandoz Inc., United States
Executive Director, Scientific Affairs
A Payer's Perspective
Tom B. Snyder, MA
Parexel International, United States
Senior Project Manager
Interchangeability: Is it Achievable? Will it Matter?
Jim Roach, MD, FACP
Pulmatrix, United States
Chief Medical Officer
Panel Discussion
All Session Speakers
United States